PTEN and glioblastoma: The knowledge of genomic changes that drive GBM gleaned from the TCGA in addition to other studies on potential molecular predictive and prognostic biomarkers in GBM including MGMT promoter and DNA methylation, LOH of chromosomes 1p and 19q, LOH 10q, IDH mutations, EGFR, ELTD1, VEGF, tumor suppressor protein p53, PTEN, p16INK4a gene, CcO, phospholipid metabolites, telomerase messenger expression (hTERT mRNA), miRNAs, cancer stem cell markers and imaging modalities as potential biomarkers are discussed and their role, if any, in clinical decision making will now be discussed (Table 2).